Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII

Kyle LaHucik

Biotech Correspondent

A biotech born out of the work of Stanford CAR-T leader Crystal Mackall is publicly unveiling its $200 million Series A Wednesday, after already going …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Altos Labs buys anti-aging startup Dorian Therapeutics

Genentech expands deal with molecular glue biotech Orionis for $105M upfront

Cocaine vaccine, a longshot attempt to quell cravings, yields mixed data in small study

Updated: Trump administration reveals 'most favored nation' drug price country targets

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Cell ther­a­py biotech from Stan­ford CAR-T leader Crys­tal Mack­all nabs $200M for PhII

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII